Indeed, we have demonstrated that pharmacological inhibition of OPRK1 prolonged time to acquisition of castration resistance and retarded castration-resistant tumor growth in multiple in vivo preclinical models of CRPC, suggesting clinical efficacy of OPRK1-targeting treatment for prolonging time to castration-resistant progression of advanced PCa. Here, OPRK1 is linked to neoplasm.